TCBPY — TC Biopharm (Holdings) Share Price
Last trade - 00:00- $0.01m
- -$1.30m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -615.23% | ||
| Return on Equity | -683.19% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 3.43 | 1.98 | 1.98 | 3.84 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TC BioPharm (Holdings) plc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies (GD-Ts) for the treatment of cancer with human efficacy data in acute myeloid leukemia. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. It is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- October 25th, 2021
- Public Since
- February 23rd, 2022
- No. of Employees
- 41
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 63,902,641
- Address
- Maxim 1, 2 Parklands Way, Holytown, ML1 4WR
- Web
- https://www.tcbiopharm.com
- Phone
- +44 1414337557
- Auditors
- Marcum LLP
Similar to TCBPY
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 23:36 UTC, shares in TC Biopharm (Holdings) are trading at $0.38. This share price information is delayed by 15 minutes.
Shares in TC Biopharm (Holdings) last closed at $0.38 and the price had moved by -99.84% over the past 365 days. In terms of relative price strength the TC Biopharm (Holdings) share price has underperformed the S&P500 Index by -99.85% over the past year.
The overall consensus recommendation for TC Biopharm (Holdings) is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreTC Biopharm (Holdings) does not currently pay a dividend.
TC Biopharm (Holdings) does not currently pay a dividend.
TC Biopharm (Holdings) does not currently pay a dividend.
To buy shares in TC Biopharm (Holdings) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.38, shares in TC Biopharm (Holdings) had a market capitalisation of $0.01m.
Here are the trading details for TC Biopharm (Holdings):
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: TCBPY
Based on an overall assessment of its quality, value and momentum TC Biopharm (Holdings) is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in TC Biopharm (Holdings) is $48.00. That is 12449.02% above the last closing price of $0.38.
Analysts covering TC Biopharm (Holdings) currently have a consensus Earnings Per Share (EPS) forecast of -£0.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like TC Biopharm (Holdings). Over the past six months, its share price has underperformed the S&P500 Index by -98.17%.
As of the last closing price of $0.38, shares in TC Biopharm (Holdings) were trading -98.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The TC Biopharm (Holdings) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on TC Biopharm (Holdings)'s directors